IPP Bureau
COVAXIN phase II/III clinical trial approved for 2-18 years
By IPP Bureau - May 13, 2021
BBIL had proposed to carry out Phase II/III clinical trial of Covaxin in the age group of 2 to 18 years
Torrent Pharma enters into agreement with Lilly for Baricitinib for Covid-19 in India
By IPP Bureau - May 13, 2021
The agreement will help ensure wider reach and access to patients in India
Lupin reports Q4FY21 consolidated PAT of Rs. 460.36 Cr
By IPP Bureau - May 13, 2021
It reported total income of Rs.15299.25 crores during the FY ended March 31, 2021
Additional Tocilizumab allocated to states: Gowda
By IPP Bureau - May 12, 2021
The additional allocation of Tocilizumab will ensure sufficient availability for COVID-19 patients and augment the government’s efforts to fight the pandemic
Dr. Reddy's launches Ertapenem in US
By IPP Bureau - May 12, 2021
The INVANZ brand and generic market had U.S. sales of approximately US $205 million MAT for the most recent twelve months ending March 2021 according to IQVIA Health
Govt. ramps up Amphotericin B manufacturing to fight Mucormycosis
By IPP Bureau - May 12, 2021
The Department of Pharma has allocated this drug amongst the states/UTs based on expected supply that will be available from May 10 to May 31, 2021
Brinton triples production of COVID-19 drug Favipiravir
By IPP Bureau - May 12, 2021
Favipiravir is close to Remdesivir, Remdesivir is used to treat moderate to severe cases while Favipiravir is used to treat mild to moderate cases
Vivimed Labs to manufacture, market Favipiravir tablets
By IPP Bureau - May 11, 2021
The tablets will be manufactured and marketed under Vivimed’s brand name “Favulous” across India
CRISIL assigns 'Positive' outlook to Jubilant Pharmova's long-term rating
By IPP Bureau - May 11, 2021
The rating withdrawal is based on the company’s request and in line with CRISIL Rating’s policy on withdrawal of ratings.
Alembic reports net profit of Rs. 71.94 Cr in Q4FY21
By IPP Bureau - May 11, 2021
Alembic has reported total income of Rs.83.79 crores during the FY ended March 31, 2021
DCGI approves anti-COVID drug developed by DRDO
By IPP Bureau - May 10, 2021
The drug accumulates in the virus infected cells and prevents virus growth by stopping viral synthesis and energy production
Remdesivir allocation made upto 16th May: Gowda
By IPP Bureau - May 10, 2021
State governments and UTs have been asked to monitor proper distribution within the state/UT covering government and private hospitals
Jubilant Pharma wins over Bracco's legal appeals in the US Court of Appeals
By IPP Bureau - May 10, 2021
Jubilant successfully challenged Bracco's patent infringement claims in an Inter Parties Review (IPR) proceeding before the U.S. Patent Office
Cipla signs agreement with Lilly to expand access to COVID-19 treatment in India
By IPP Bureau - May 10, 2021
Baricitinib was issued a restricted emergency use approval by the Central Drugs Standard Control Organization (CDSCO)
Sun Pharma signs agreement with Eli Lilly for expanding access to Baricitinib
By IPP Bureau - May 10, 2021
Baricitinib is used in combination with remdesivir for the treatment of suspected or laboratory confirmed COVID-19
